Merck Starts Phase III Cancer Vaccine Trial
Posted on: Monday, 26 February 2007, 12:00 CST
Merck KGaA has enrolled the first patient in a phase III trial, assessing the efficacy and safety of the vaccine Stimuvax as a potential treatment for patients with unresectable stage III non-small cell lung cancer.
The trial is being conducted by Merck and its US affiliate EMD Pharmaceuticals pursuant to the terms of a collaboration. Merck obtained the exclusive worldwide licensing rights for Stimuvax from Biomira.
The trial will evaluate patients with documented unresectable stage III non-small cell lung cancer (NSCLC) who have had a response or stable disease after at least two cycles of platinum based chemo-radiotherapy. Currently, there are no approved maintenance therapies for patients responding to first-line treatment for unresectable stage III NSCLC.
Stimuvax is designed to induce an immune response to cancer cells that express MUC1, a protein antigen widely expressed on common cancers. MUC1 is over expressed on many cancers such as lung cancer, breast cancer and colorectal cancer. Stimuvax is thought to work by stimulating the body's immune system to identify and destroy cancer cells expressing MUC1.
Overall study results from an earlier phase IIb trial were not statistically significant. But Stimuvax showed a median survival of 30.6 months versus 13.3 months in the control group - an improvement of 17.3 months.
Source: Datamonitor
Related Articles
- Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia
- Northwestern Memorial Study Tests Cancer Drug on Scleroderma Patients
- Pancreatic Cancer Therapy Trial Starts
- Cell Therapeutics, Inc. (CTI) Closes PGT305 (PIONEER) Lung Cancer Clinical Trial; New PGT306 Protocol to Be Submitted to FDA By Year End
- Cell Therapeutics, Inc. (CTI) Temporarily Suspends Enrollment on PIONEER Lung Cancer Clinical Trial; Current Patients Continue to Be Treated
- 17,500 Participants Needed to Enroll in Major Colorectal Cancer Clinical Trials; CancerTrialsHelp.Org Launches QuickLink
- IDM Closes Enrollment to Its EP-2101 Therapeutic Vaccine Trial in Patients With Non-Small Cell Lung Cancer
- Study looks at factors influencing African-American women's decisions to join cancer screening trial
- Sonus Starts Key Cancer Drug Trial
- First International Registry of Patients With Early Stage Breast Cancer Launched
 |
 |
User Comments (0)
RSS Feeds